Transcriptome sequencing and survival analysis of noncirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma

doi:10.3969/j.issn.1006-7795.2023.05.016

Abstract

Abstract: Objective Transcriptome sequencing and bioinformatics analysis were used to explore the transcriptional characteristics and survival analysis of non-cirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma (HCC). Methods The differentially expressed genes in non-cirrhotic HBV-related HCC were obtained by transcriptome sequencing. The biological functional processes and signaling pathways involved in the differentially expressed genes were obtained by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. The key genes were obtained by gene-gene function interaction network analysis, and the key genes were analyzed for survival prognosis using the cancer genome atlas (TCGA) database’s HCC cohort. Results A total of 3 672 up-regulated differential genes and 2 715 down-regulated differential genes were identified. The GO functional enrichment analysis mainly involved cell differentiation, DNA replication, DNA repair, inflammation response, immune response, cell adhesion, etc, while the KEGG pathway enrichment mainly included cell cycle, oxidative phosphorylation, p53 signaling pathway,tumor necrosis factor（TNF） signaling pathway, and nuclear factor kappa-B（NF-κB） signaling pathway. Among them, high expression of mitogen-activated protein kinase 3（MAPK3）, ras-related C3 cotulinum toxin substrate 1（RAC1）,phospholipase C beta 1（PLCβ1）, catenin beta 1（CTNNβ1）, non-metastatic cells 1（NME1）, and non-metastatic cells 6（NME6） was associated with poor prognosis in HCC patients (P<0.05), while low expression of FYN, cytochrome P450 2C8（CYP2C8）, and cytochrome P450 2C9（CYP2C9） was associated with poor prognosis in HCC patients (P<0.05). Conclusions Non-cirrhotic HBV-related HCC involves multiple biological processes and alterations in signaling pathways, and the key genes related to the survival and prognosis of HCC patients provide new clues for understanding the mechanism of HBV-related HCC in non-cirrhosis patients.

Key words: non-cirrhotic hepatocellular carcinoma, differentially expressed genes, signalling pathways

CLC Number:

Wan Yan, Liu Fang, Guo Shan, Wu Jian. Transcriptome sequencing and survival analysis of noncirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma[J]. Journal of Capital Medical University, 2023, 44(5): 811-820.

References

［1］Kelley R K, Greten T F. Hepatocellular carcinoma-origins and outcomes［J］. N Engl J Med, 2021, 385(3): 280-282.
［2］Desai A, Sandhu S, Lai J P, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review［J］. World J Hepatol, 2019, 11(1): 1-18.
［3］Cucchetti A, Zhong J H, Berhane S, et al. The chances of hepatic resection curing hepatocellular carcinoma［J］. J Hepatol, 2020, 72(4): 711-717.
［4］Skidmore Z L, Kunisaki J, Lin Y, et al. Genomic and transcriptomic somatic alterations of hepatocellular carcinoma in non-cirrhotic livers［J］. Cancer Genet, 2022, 264/265: 90-99.
［5］Hyuna S, Jacques F, Rebecca L S, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209-249.
［6］Yang Y Q, Wen Z Y, Liu X Y, et al. Current status and prospect of treatments for recurrent hepatocellular carcinoma［J］. World J Hepatol, 2023, 15(2): 129-150.
［7］Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma［J］. J Hepatol, 2016, 64(1 Suppl): S84-S101.
［8］Farazi P A, DePinho R A. Hepatocellular carcinoma pathogenesis: from genes to environment［J］. Nat Rev Cancer, 2006, 6(9): 674-687.
［9］Moon H, Ro S W. MAPK/ERK signaling pathway in hepatocellular carcinoma［J］. Cancers (Basel), 2021, 13(12): 3026.
［10］Sauzeau V, Beignet J, Vergoten G, et al. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma［J］. Pharmacol Res, 2022, 179: 106220.
［11］Liang S H, Guo H R, Ma K, et al. A PLCβ1-PI3K-AKT signaling axis activates EMT to promote cholangiocarcinoma progression［J］. Cancer Res, 2021, 81(23): 5889-5903.
［12］Javanmard D, Najafi M, Babaei M R, et al. Investigation of CTNNβ1 gene mutations and expression in hepatocellular carcinoma and cirrhosis in association with hepatitis B virus infection［J］. Infect Agent Cancer, 2020, 15: 37.
［13］Yang J, Lv Z H, Huang J T, et al. High expression of NME1 correlates with progression and poor prognosis in patients of hepatocellular carcinoma［J］. Int J Clin Exp Pathol, 2017, 10(8): 8561-8568.
［14］Proust B, Radi M, Vidac∨ek N , et al. NME6 is a phosphotransfer-inactive, monomeric NME/NDPK family member and functions in complexes at the interface of mitochondrial inner membrane and matrix［J］. Cell Biosci, 2021, 11(1): 195.
［15］Huang C K, Zhou J J, Nie Y, et al. A new finding in the key prognosis-related proto-oncogene FYN in hepatocellular carcinoma based on the WGCNA hub-gene screening trategy［J］. BMC Cancer, 2022, 22(1): 380.
［16］Wang X K, Yu T D, Liao X W, et al. The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma［J］. Cancer Med, 2018, 7(4): 966-980.

[1]	Du Feng, Xu Rui, Zhao Mengran, Ji Xu, Su Jiayi, Qiu Yuting, Zhu Shengtao, Wu Jing, Li Peng, Zhang Shutian. The role and mechanism of SOX4 in Helicobacter pylori-mediated gastric mucosal epithelial dysplasia [J]. Journal of Capital Medical University, 2025, 46(4): 644-653.
[2]	Liu Juan, Zhang Zheng, Li Peng. Clinical characteristics of autoimmune gastritis patients complicated with early gastric cancer [J]. Journal of Capital Medical University, 2025, 46(4): 670-675.
[3]	Liu Honglei, Yang Yingliang, Li Ronghao, Zhu Congmin, Zhang Xu. Application of artificial intelligence in the study of cancer diagnosis and treatment research [J]. Journal of Capital Medical University, 2025, 46(3): 395-400.
[4]	Gao Tianbo, Ge Yang, An Guangyu, Yao Jiannan, Jiang Yuliang, Liu Heshu, Yan Rui. Abnormal O-glycosylation mediated by the deficiency of molecular chaperone Cosmc or T-synthase regulates the expression of miRNAs in colorectal cancer exosomes [J]. Journal of Capital Medical University, 2025, 46(3): 401-409.
[5]	Liu Xiaoqian, Sun Kai, Wang Xiaolin, Zhao Qianqian, Wu Xiaoxiao, Shen Fangqi, Chen Xi, Tian Chenxu, Wu Di, Song Chunhua, Xu HongXia, Cong Minghua, Shi Hanping, Jia Pingping. Comparison of the prognostic value of 15 nutritional/inflammatory indicators in postoperative cancer patients [J]. Journal of Capital Medical University, 2025, 46(3): 410-419.
[6]	Li Yawei, Yang Shoubo, Yin Shuo, Li Wenbin, Chen Feng. Clinical efficacy analysis of hetrombopag in the treatment of cancer therapy included thrombocytopenia for germ cell tumors [J]. Journal of Capital Medical University, 2025, 46(3): 420-426.
[7]	Wang Qinglian, Teng Ying, Qiao Wenying, Chen Jinglong, Ding Xiaoyan. Comparative analysis of efficacy and safety of different regimens in the treatment of AIDS-related Burkitt lymphoma: a single-center retrospective study [J]. Journal of Capital Medical University, 2025, 46(3): 427-435.
[8]	Wang Jingwen, Li Zhenjun, Lyu Liangcheng, Yao Xiaoyu, Ding Ning. B cell receptor signaling pathway and its therapeutic implications in B-cell lymphoma [J]. Journal of Capital Medical University, 2025, 46(3): 436-441.
[9]	Jiang Haiping, Yin Shuo, Li Shenglan, Li Wenbin. The progress in the role and application of neutrophils in glioma [J]. Journal of Capital Medical University, 2025, 46(3): 448-454.
[10]	Jing Fang, Jing Chao. Micro RNA-338-3p regulates proliferation, apoptosis, migration, and invasion of ovarian cancer cells through ERBB2 [J]. Journal of Capital Medical University, 2025, 46(3): 527-537.
[11]	Yang Peiyi, Duan Chao, Wang Shengcai, Jin Mei, Zhang Dawei, Fu Libing, Yu Tong, Liu Zhikai, Ma Xiaoli, Ni Xin, Su Yan. Analysis of clinical features and prognosis in pediatric malignant solid tumors of head and neck in single-center [J]. Journal of Capital Medical University, 2025, 46(3): 545-552.
[12]	Meng Lingzhao, Qu Xiaopeng, Tao Pengyu, Yang Fan, Rao Yuansheng, Wang Ru, Fang Jugao. Application value of low-temperature plasma bipolar forceps in thyroid cancer surgery [J]. Journal of Capital Medical University, 2025, 46(3): 553-558.
[13]	Shi Feng, ZhaoYanjie, Gao Ying, Song Qingkun. Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis [J]. Journal of Capital Medical University, 2025, 46(2): 210-215.
[14]	Fan Yunpeng, Xiong Tianyu, Yang Kun, Liu Zhanliang, Jin Song, Xie Ping, Niu Yinong. Prediction model for extraprostatic extension of prostate based on MRI and clinical indicators [J]. Journal of Capital Medical University, 2025, 46(2): 243-251.
[15]	Xiong Tianyu, Zhao Youquan, Xie Ping, Niu Yinong. Advances in research on the interaction mechanisms between androgen receptor and PI3K/AKT pathways in prostate cancer [J]. Journal of Capital Medical University, 2025, 46(2): 269-282.